Hologic (HOLX) Goes Private: Blackstone and TPG Close $17 Billion Acquisition
🎉 Hologic completed its privatization on April 7, 2026, as Blackstone and TPG acquired the medical device firm for up to $79 per share.
💰 Shareholders received an immediate cash payment of $76 per share upon closing of the transaction.
🤝 Minority investors including Abu Dhabi Investment Authority and GIC participated in the deal structure.
⏳ The remaining valuation potential of up to $3 per share is tied to Breast Health segment revenue targets for 2026-2027 via contingent value rights.
📉 Recent quarterly earnings missed analyst estimates with revenue at $1.05 billion and EPS at $1.04.
👋 CEO Stephen MacMillan stepped down after a 12-year tenure, replaced by new CEO Joe Almeida who previously led Baxter International.
🏢 Blackstone and TPG are now the sole owners of the women's health technology firm following delisting from Nasdaq.
📊 The company holds strong balance sheet metrics including $4.13 billion in trailing revenue and a gross profit margin of 60%.
🔄 Employee stock options were settled through cash or CVR distributions, while out-of-the-money options were eliminated without compensation.
🔚 Final trading session of HOLX shares concluded at $76.01, closely matching the deal price and previous 52-week high.
📈 The investment bank InvestingPro rated Hologic with a "GREAT" financial health status before privatization.
🎯 Analysts lowered future earnings projections leading up to the transaction close, though final recommendations remained Buy-rated.
- Hologic was acquired by Blackstone and TPG at a valuation of up to $79 per share, representing significant upside from the immediate $76 cash payment received by shareholders.
- Investors are eligible for an additional contingent value right worth up to $3 per share if specific worldwide revenue benchmarks for the Breast Health segment are met in fiscal years 2026 and 2027.
- The transaction involved participation from Abu Dhabi Investment Authority and GIC as minority investors, adding credibility to the new ownership structure.
- Prior to privatization, Hologic demonstrated strong financial health with $4.13 billion in trailing twelve-month revenue and a current ratio exceeding 4.
- Joe Almeida, newly appointed CEO, brings extensive experience including previous leadership roles at Baxter International and Covidien, suggesting capable management under the new private equity owners.
- InvestingPro had designated Hologic with a 'GREAT' financial health rating before the privatization concluded.
- Despite missing some recent quarterly targets, final analyst recommendations remained positive with a Buy rating and an $83 price objective indicating potential upside over the transaction value.
- Hologic's most recent quarterly performance missed analyst consensus for both revenue ($1.05 billion vs $1.07 billion) and adjusted earnings per share ($1.04 vs $1.09), signaling underlying growth concerns before the takeover.
- A portion of the $79 per share acquisition valuation is contingent on future Breast Health division revenue benchmarks during fiscal years 2026 and 2027, meaning shareholders could receive significantly less than the full price if performance targets are not met.
- Employee stock options were resolved largely through cash settlements and CVR-linked distributions, while significantly out-of-the-money options were eliminated without compensation, causing potential dissatisfaction among certain equity holders.
- Six financial analysts lowered earnings projections prior to the transaction closing, suggesting institutional caution despite the 'Great' financial health rating given by InvestingPro before privatization concluded.
- The new CEO Joe Almeida is now designated as the sole board director, effectively consolidating executive control and eliminating independent board oversight following the departure of 12-year veteran Stephen MacMillan.
